CanSino’s Td5cp Booster Wins Priority Review After NDA Acceptance in China
I'm LongbridgeAI, I can summarize articles.CanSino Biologics announced that China's National Medical Products Administration accepted its new drug application for the Td5cp Adolescent and Adult vaccine. This five-component booster targets adolescents and adults, addressing a gap in China's immunization schedule. The application has been granted priority review, potentially accelerating market entry. Analysts maintain a 'Buy' rating with a HK$64 price target for CanSino stock.
CanSino Biologics, Inc. Class H ( (HK:6185) ) has provided an update.
CanSino Biologics Inc. has announced that China’s National Medical Products Administration has accepted its new drug application for the Td5cp Adolescent and Adult vaccine. The product is a tetanus, reduced diphtheria and acellular pertussis five-component booster designed for individuals aged six years and above.
The vaccine targets a major gap in China’s immunization schedule, as the country currently lacks an approved booster for diphtheria, tetanus and acellular pertussis in adolescents and adults. Building on its previously approved DT3cP Infant vaccine, the new formulation adds two pertussis antigens to enhance stability and batch consistency, and has been granted priority review, potentially accelerating market entry and reinforcing CanSino’s position in the domestic vaccine market.
The most recent analyst rating on (HK:6185) stock is a Buy
with a HK$64.00 price target.
To see the full list of analyst forecasts on CanSino Biologics, Inc. Class H stock,
see the HK:6185 Stock Forecast page.
More about CanSino Biologics, Inc. Class H
CanSino Biologics Inc. is a China-based biopharmaceutical company specializing in the research, development and production of innovative vaccines. The company focuses on addressing unmet public health needs in its domestic market, with a portfolio that includes acellular diphtheria, tetanus and pertussis combination vaccines targeting different age groups.
Its strategy centers on expanding vaccine coverage across infants, adolescents and adults, aligning with global immunization practices while filling gaps in China’s routine vaccination programs. This positioning aims to strengthen its role in the country’s preventive healthcare infrastructure and the broader vaccine industry.
Average Trading Volume: 815,617
Technical Sentiment Signal: Sell
Current Market Cap: HK$10.77B
Find detailed analytics on 6185 stock on TipRanks’ Stock Analysis page.